Latest news with #JohnBode
The Hill
18-07-2025
- Business
- The Hill
Coke sweetener switch threatens US jobs, corn refiners say
President Trump's claim that Coca-Cola is switching to cane sugar has left a bitter taste for corn syrup lobbyists, who warn that the recipe shake-up will threaten the income of thousands of American farmers. The Corn Refiners Association, which represents high-fructose corn syrup producers, said the change threatens thousands of jobs and risks devastating primarily Midwest American farms. 'There are about 10,000 people working in corn refining. One-third of the corn refined goes for making high-fructose corn syrup,' said John Bode, president and CEO of the Corn Refiners Association. 'If we eliminate high-fructose corn syrup use, that's going to have a very substantial effect on at least a third of the production, probably significantly more of the corn refining industry,' he continued. 'So that's thousands of jobs.' Despite Trump's announcement Wednesday, Coca-Cola has yet to confirm the change. The announcement has reignited a decades-long food fight between the two sweeteners, with share prices for some major corn syrup companies experiencing dramatic drops Thursday. According to the American Medical Association, there are no known nutritional differences between high-fructose corn syrup and cane sugar, but neither should be consumed in large quantities.
Yahoo
23-03-2025
- Business
- Yahoo
Zevra Therapeutics Independent Director Acquires 33% More Stock
Whilst it may not be a huge deal, we thought it was good to see that the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Independent Director, John Bode, recently bought US$80k worth of stock, for US$7.96 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 33%. Notably, that recent purchase by John Bode is the biggest insider purchase of Zevra Therapeutics shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$8.01. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Zevra Therapeutics share holders is that insiders were buying at near the current price. Zevra Therapeutics insiders may have bought shares in the last year, but they didn't sell any. They paid about US$6.89 on average. To my mind it is good that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out our latest analysis for Zevra Therapeutics There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them). Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 6.6% of Zevra Therapeutics shares, worth about US$29m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Zevra Therapeutics insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Zevra Therapeutics. Our analysis shows 2 warning signs for Zevra Therapeutics (1 is concerning!) and we strongly recommend you look at them before investing. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
